Phytocannabinoids Alter CYP Enzymes (PubMed, 2026)

Tier 1: Established: peer-reviewed research or government health authority
Publisher: European Journal of Drug Metabolism and Pharmacokinetics (Chaphekar et al., 2026; PMID 42663925) · Published: September 16, 2026 · Accessed: September 16, 2026

Visit the source ↗

Claims this source supports

• In primary human hepatocyte cultures, acute exposure to CBD, CBN or a cannabinoid mix inhibited CYP1A2 activity in a concentration-dependent manner.
• Chronic exposure to THC and to a cannabinoid mix significantly increased CYP3A4 activity and expression; the mix showed mild CYP3A4 inhibition acutely.
• The authors conclude cannabinoids selectively alter CYP enzyme activity and expression, which may change exposure of co-administered drugs via metabolic drug-drug interactions.